The two legs send the money to different places: a fresh issue raises new capital for the company, while an offer for sale is existing shares being sold by existing shareholders, whose proceeds go to those sellers and not to the company.
Source: All the financial information for listed industry peers mentioned above is on a consolidated basis (unless otherwise available only on standalone basis) and is sourced from the annual reports / other publicly available information as available on the website of peers for the financial year ended March 31, 2026. *Financial information of the Company has been derived as at or for the year ended March 31, 2026. The Price/earnings ratio has been computed based on the closing market price of equity shares on BSE as on July 30, 2026, divided by the Diluted EPS for year ended March 31, 2026 Return on Net Worth (%) is calculated as profit for the year attributable to owners of the Parent company divided by Net worth as at the end of the year. For our Company, Net worth has been computed as the aggregate of Equity share capital, Retained earnings, Securities premium, Other Reserves, Put option liability towards non-controlling interest shareholders and Money received against share warrants. For Poly Medicure Limited, Metropolis Healthcare Limited and Vijaya Diagnostics Centre Limited, Net worth has been computed as the aggregate of Equity share capital and Other Equity. For Dr. Lal Pathlabs Limited, Net worth has been computed as the aggregate of Equity share capital and Other Equity less Capital reserve. Net asset value (NAV) per Equity Share is calculated by dividing Net worth as of the end of the year by the number of outstanding equity shares as at the year end.
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care ("POC") diagnostics company focused on delivering accurate, rapid, and cost-effective healthcare technologies for infectious and non-communicable diseases. The company has developed the 'Truenat' platform, a portable polymerase chain reaction ("PCR") system that provides decentralized diagnosis within an hour, even in resource-limited settings. As of March 31, 2025, the platform is patented in over 100 countries and offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, HIV, and HPV through 42 assays. The 'Truenat' TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiary Prognosys, associate OptraScan, and collaboration partner UE Lifesciences. The company operates five manufacturing facilities in India - two in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Karnataka). These units manufacture diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems. The company has a global presence in over 80 countries with 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and through distributors to public health programs, diagnostic laboratories, and hospitals. The company generates revenues from device sales as well as recurring revenues from proprietary test kits. As of March 31, 2025, the company employed 1,000 permanent employees and 1,511 contract labourers.
What is the Molbio Diagnostics IPO price band?+
The price band for the Molbio Diagnostics IPO has not been announced yet. It is set by the company and its bankers and stated in the offer document.
When does the Molbio Diagnostics IPO open and close?+
The issue opens on 10 Aug 2026 and closes on 12 Aug 2026. Dates can move — the registrar and the exchange notices are the record.
When is the Molbio Diagnostics IPO allotment?+
Allotment is scheduled for 13 Aug 2026. The basis of allotment is published by the registrar to the issue. BuyUnlistedShares does not accept, process or track IPO applications.
When does Molbio Diagnostics list?+
Listing is scheduled for 17 Aug 2026 on NSE, BSE.
Where will Molbio Diagnostics be listed?+
Molbio Diagnostics is proposed for listing on NSE, BSE. It is a mainboard issue.
What is the difference between the fresh issue and the offer for sale in the Molbio Diagnostics IPO?+
Money raised through the fresh issue goes to the company, which spends it on the purposes set out in the offer document. Money raised through the offer for sale goes to the shareholders who are selling, not to the company. That is a fact about how the issue is structured, not a view on it.
Who is the registrar for the Molbio Diagnostics IPO?+
The registrar to the issue is Kfin Technologies Ltd. (040-79615565), molbio.ipo@kfintech.com.
Where can I check the Molbio Diagnostics IPO allotment status?+
Allotment status is published by the registrar on its own official portal: https://ipostatus.kfintech.com/. Use the registrar's site directly — BuyUnlistedShares does not ask for PAN, application numbers or any other applicant detail.